Agalsidase beta biosimilar (JCR Pharmaceuticals)

Product Name :
Agalsidase beta biosimilar (JCR Pharmaceuticals)

Search keywords :
Alpha-Gal

drugId :
null

Target Vo:
Glycosphingolipid

Target Vo Short Name :
Glycosphingolipid

Moa_Name:
glycosphingolipid hydrolysis activators

First Approval Country :
Japan

First Approval Date Filter:
2018

Origin Company_Name :
Jcr Pharmaceuticals Co Ltd

Active Company_Name :
Glaxosmithkline Plc

Active Indication_Name:
Fabry Disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
ERK1/2 Rabbit mAb Purity
Brazikumab supplier
MCM2 Antibody (YA705): MCM2 Antibody (YA705) is a non-conjugated and Mouse origined monoclonal antibody about 102 kDa, targeting to MCM2 (2B5). It can be used for WB,IHC-F,IHC-P,ICC/IF,FC,IP assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts